<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198354</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0002</org_study_id>
    <nct_id>NCT00198354</nct_id>
  </id_info>
  <brief_title>Stage I/II NSCLC Perioperative Chemotherapy</brief_title>
  <official_title>Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of chemotherapy to lung cancer surgery is now considered as the standard of
      care. Solid data support postoperative chemotherapy but only few results are available in the
      preoperative setting. To define which timing of perioperative chemotherapy offers the best
      survival improvement, the IFCT 0002 study is conducted in France.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multicenter study, patients are randomized to receive either two preoperative
      chemotherapy cycles plus two additional preoperative cycles if they respond to chemotherapy,
      or two preoperative plus two postoperative cycles in case of response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare 3-Years survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Objective response rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Non-small Cell Lung Cancer Stage I and II</condition>
  <condition>Peri-operative Chemotherapy</condition>
  <arm_group>
    <arm_group_label>A: pre-operative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: pre-operative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: peri-operative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: peri-operative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine + cisplatine</intervention_name>
    <description>gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)</description>
    <arm_group_label>A: pre-operative chemotherapy</arm_group_label>
    <arm_group_label>B: pre-operative chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatine</intervention_name>
    <description>paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)</description>
    <arm_group_label>C: peri-operative chemotherapy</arm_group_label>
    <arm_group_label>D: peri-operative chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically or cytologically NSCLC stade I or II Resectable disease WHO performance
        status of 2 or less

        Exclusion Criteria:

        NSCLC stage III or IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Depierre, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Besancon - Pneumologie</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>Official website</description>
  </link>
  <results_reference>
    <citation>Westeel V, Quoix E, Puyraveau M, Lavolé A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Rivière A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarié E, Morin F, Depierre A, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013 Aug;49(12):2654-64. doi: 10.1016/j.ejca.2013.04.013. Epub 2013 Jun 1.</citation>
    <PMID>23735703</PMID>
  </results_reference>
  <results_reference>
    <citation>de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20.</citation>
    <PMID>22434665</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol. 2012 May;7(5):841-9. doi: 10.1097/JTO.0b013e31824c7d92.</citation>
    <PMID>22722786</PMID>
  </results_reference>
  <results_reference>
    <citation>Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT). High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther. 2012 May;11(5):1203-13. doi: 10.1158/1535-7163.MCT-11-0899. Epub 2012 Mar 12.</citation>
    <PMID>22411898</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

